Cheng Du Sheng Nuo Biotec Co., Ltd. Class A
SSSE:68811715.21
CNY
-0.50
(-3.18%)
ISIN
CNE1000051M8
Return %
Stock
S&P 500
1Y
-45.65
14.20
3Y
8.01
81.12
5Y
18.30
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Yong Jun Wen
- Full Time Employees
- 1,605
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 98, Da'an Road, Dayi County Chengdu SI China 611330
- IPO Date
- Jun 3, 2021
- Website
- snbiopharm.com
- Similar Companies
- Business
- ChengDu ShengNuo Biotec Co.,Ltd. (688117.SS) engages in the research, development, production, sales, and export of peptide drugs, specializing in polypeptide active pharmaceutical ingredients (APIs), peptide formulations, cosmetic bioactive peptides, and contract development and manufacturing organization (CDMO) services for innovative and generic peptide drugs. The company manufactures a range of products including tablets of solid preparations, bottles of freeze-dried powder injections, small-volume injections, pre-filled injections, and card-type injections; key offerings encompass APIs and formulations such as Liraglutide, Semaglutide, Tirzepatide, Enfuvirtide, Bivalirudin, Eptifibatide, Atosiban Acetate, Octreotide Acetate, Somatostatin, Thymalfasin (Thymosin alpha 1), Carbetocin, Esmopeptide (Exenatide) injection, Ganirelix Acetate injection, Nesiritide, Thymopentin, and cosmetic peptides. It provides full-industrial-chain capabilities from drug discovery and preclinical research through clinical trials to commercial manufacturing, with US-DMF filings for multiple peptide APIs and facilities certified by the US FDA. Founded in 2001 and headquartered at No. 258, Section 1, Xueshan Avenue, Qingxia Street, Dayi County, Chengdu, Sichuan Province, China, the company operates primarily in the healthcare sector, focusing on drug manufacturers specializing in peptides for therapeutic areas including digestive system disorders, immunity, tumors, hepatitis B, diabetes, obstetrics, heart failure, and chronic obstructive pulmonary disease. Chengdu Shengnuo Biopharm Co., Ltd. serves as a wholly-owned subsidiary, handling specialized production with a registered capital of CNY 50 million and over 50 key technologies for large-scale peptide synthesis. The firm went public on the STAR Market in 2021, employs over 1,381 staff, and maintains four major production bases alongside advanced R&D centers totaling more than 12,700 square meters for process research, pilot production, GMP workshops, and analysis. In recent developments, the company voluntarily disclosed in September 2025 that its Esmopeptide (Exenatide) injection and Ganirelix Acetate injection received drug registration certificates from Chinese regulatory authorities, marking new product approvals for commercialization. It inaugurated a new headquarters in December 2023 to support expansion and operational growth. Additionally, Chengdu Shengnuo Biopharm has advanced complex peptide syntheses like Semaglutide, Tirzepatide, and Retatrutide, led national major projects under the 11th Five-Year Plan for drugs including Atosiban Acetate and Carbetocin, and completed domestic first-approved generics such as Enfuvirtide and Carbetocin injections, with ongoing CDMO support for over 50 innovative drugs, more than 30 in clinical trials.